$REPL News

Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed

Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate

Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit

Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19

Replimune Group, Inc. (REPL) Shareholder/Analyst Call Transcript

Replimune Group, Inc. (REPL) Shareholder/Analyst Call - Slideshow

Replimune Receives FDA Accelerated Approval For TUDRIQEVTM In Combination With Nivolumab For Treatment Of Adults With Unresectable Advanced Cutaneous Melanoma

Leerink Partners Upgrades Replimune Group to Outperform, Raises Price Target to $17

Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $12

Cantor Fitzgerald Upgrades Replimune Group to Overweight

'US FDA panel backs Replimune skin cancer drug study data'- Reuters

Replimune's RP1 Drug Probably Works, But It's Not A Buy Yet

Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Replimune Group Q4 EPS $(0.76) Misses $(0.71) Estimate

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date And Expects Adcom Meeting In Late July

Replimune: Modeling The Coin Flip Of FDA Approval

Why Is REPL Stock Gaining In Pre-Market Today?

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting